Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report source : Www.inventivapharma.com save search
Inventiva reports 2023 First Quarter Financial Information and provides a corporate update
Published: 2023-05-16 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -1.57%
H: 1.19%
C: 1.19%
update financial
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Published: 2023-03-30 (Crawled : 10:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -1.6%
H: 2.7%
C: -6.22%
report universal
Inventiva reports its 2022 Full-Year Results
Published: 2023-03-29 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -1.6%
H: 2.7%
C: -6.22%
results
Inventiva reports preliminary financial results for Full-Year 2022
Published: 2023-02-14 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -0.17%
H: 1.71%
C: 1.71%
financial
Inventiva reports 2022 Third Quarter Financial Information
Published: 2022-11-10 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: 7.95%
H: 23.88%
C: 0.38%
financial
Inventiva Reports 2022 First-Half Financial Information
Published: 2022-07-28 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -3.0%
H: 0.0%
C: -1.11%
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
Published: 2022-05-16 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: 1.02%
H: 4.02%
C: 4.02%
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
Published: 2022-03-11 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
| Email alert
Add to watchlist
ces report
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
Published: 2022-03-07 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -0.18%
H: 2.55%
C: 1.91%
psoriasis one report results nash milestone
Inventiva reports cash position and revenues for Full-Year 2021
Published: 2022-02-14 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: 1.36%
H: 3.54%
C: 3.54%
report positive
Inventiva reports 2021 Third Quarter Financial Information
Published: 2021-11-10 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -0.63%
H: 2.33%
C: 2.33%
Inventiva reports 2021 first half financial results and provides a corporate update
Published: 2021-09-20 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: -0.14%
H: 1.0%
C: -0.33%
financial results results
Inventiva Reports First-Half of 2021 Financial Information
Published: 2021-07-28 (Crawled : 21:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: 0.93%
H: 0.43%
C: -4.5%
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
Published: 2021-05-12 (Crawled : 20:00) - inventivapharma.com
IVA | $3.35 -2.9% -2.99% 8.5K
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 1.07%
disease collaboration
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.